/Companies

Tharimmune

Bridgewater, US · Delaware corporation · 1 known investors

Find your way into Tharimmune

Sign up to see every warm intro you have to Tharimmune

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Tharimmune team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Founders & leadership

TH
Thomas HessChief Financial Officer
SA
Sireesh AppajosyulaChief Operating OfficerSireesh Appajosyula is Chief Operating Officer at Tharimmune, a biotechnology company developing therapies for autoimmune and oncologic diseases.
RM
Randy MilbyChief Executive Officer and Chairman

Board

LA
Lynne A/ BuiBoard director
SP
Sanam ParikhBoard director
LM
Leonard MazurBoard director
KA
Kelly AndersonBoard director

Investors · 1

GravitasreportedChapel Hill

How we know: press coverage · funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$9.6M disclosed across 5 rounds · 2024–2025

▶$1.2MraisedApr 2026 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Vincent LoPrioreDirector
  • Clay KahlerDirector
  • Jill SommersDirector
  • Angela RadkowskiExecutive Officer
  • Mark ToomeyExecutive Officer
  • Sireesh AppajosyulaDirector
  • Jacob AsburyExecutive Officer
  • Gary StetzDirector
  • William WileyDirector
  • Mark WendlandExecutive Officer, Director
Offering amount
$1.2M
Amount sold
$1.2M
Sales commissions
$85.8K
Placement agents
President Street Global LLC
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.7MraisedApr 2026 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark WendlandExecutive Officer, Director
  • Angela RadkowskiExecutive Officer
  • Clay KahlerDirector
  • Sireesh AppajosyulaDirector
  • Jill SommersDirector
  • Gary StetzDirector
  • Mark ToomeyExecutive Officer
  • Vincent LoPrioreDirector
  • William WileyDirector
  • Jacob AsburyExecutive Officer
Offering amount
$1.7M
Amount sold
$1.7M
Sales commissions
$121.8K
Placement agents
President Street Global LLC
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedJul 2025 · 30 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Clay KahlerDirector
  • James Gordon LiddyDirector
  • Sireesh AppajosyulaExecutive Officer, Director
  • Gary StetzDirector
  • Sanam ParikhDirector
  • Vincent LoPrioreExecutive Officer, Director
Offering amount
$2.5M
Amount sold
$2.5M
Sales commissions
$175K
Placement agents
President Street Global, LLC
First sale
Jun 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedDec 2024 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas HessExecutive Officer
  • Sireesh AppajosyulaExecutive Officer, Director
  • Lynne A/ BuiDirector
  • Sanam ParikhDirector
  • Leonard MazurDirector
  • Kelly AndersonDirector
  • Randy MilbyExecutive Officer, Director
Offering amount
$2M
Amount sold
$2M
Sales commissions
$121.2K
Placement agents
President Street Global, LLC
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.1MraisedJun 2024 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Randy MilbyExecutive Officer, Director
  • Kelly AndersonDirector
  • Leonard MazurDirector
  • Sireesh AppajosyulaExecutive Officer, Director
  • Thomas HessExecutive Officer
  • Lynne A BuiDirector
Offering amount
$2.1M
Amount sold
$2.1M
Sales commissions
$125K
Placement agents
President Street Global, LLC
First sale
Jun 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who are Tharimmune's investors?
Tharimmune's investors include Gravitas.
How much funding has Tharimmune raised?
Tharimmune has disclosed $9.6M raised across 5 rounds.
Where is Tharimmune headquartered?
Tharimmune is headquartered in Bridgewater, US.